Latest / Chip Stock Investor Podcast
Episode 221: A Best Stock For 2025 and Beyond? Chip Stock Investors, Check This 1 Top Growth Stock Out Now
Check out the New Bond account with an initial APY of 6.9%, only at https://public.com/csi In this episode of Chip Stock Investor, the focus shifts to the biotech and big pharma sector, specifically examining Vertex Pharmaceuticals (VRTX). Following work on semiconductors' contribution to healthcare technology, Nick and Kasey discuss Vertex's current operations. Cystic fibrosis treatments and a partnership with CRISPR Therapeutics on a new treatment for blood diseases are the current moneymakers. But Vertex has a wide pipeline of other potential treatments, including those for type 1 diabetes…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.